Pages that link to "Q40727012"
Jump to navigation
Jump to search
The following pages link to Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials (Q40727012):
Displaying 50 items.
- Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention (Q24793199) (← links)
- The Use of Heparin during Endovascular Peripheral Arterial Interventions: A Synopsis (Q26748703) (← links)
- Advances in adjunctive pharmacological therapy for percutaneous coronary interventions (Q28181298) (← links)
- A guide to drug use during percutaneous coronary intervention (Q28194376) (← links)
- Antithrombotic therapy in the acute phase of unstable angina (Q28194745) (← links)
- Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression (Q30248368) (← links)
- Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention (Q33345884) (← links)
- Bivalirudin: a review (Q33367230) (← links)
- Antiplatelet and Anticoagulant Drugs in Interventional Radiology (Q33395898) (← links)
- Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factors (Q33900654) (← links)
- Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes (Q34336816) (← links)
- Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution (Q34384938) (← links)
- Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines. (Q34445660) (← links)
- Anticoagulant and antiplatelet drugs (Q34465106) (← links)
- Bivalirudin: a review of its potential place in the management of acute coronary syndromes (Q34585171) (← links)
- Choice of agents to limit the coagulation cascade in acute coronary syndromes (Q34674164) (← links)
- Unfractionated versus fractionated heparin for percutaneous coronary intervention (Q34674179) (← links)
- Heparin dose during percutaneous coronary intervention: how low dare we go? (Q34858594) (← links)
- Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. (Q35170842) (← links)
- Low‐molecular‐weight heparin during percutaneous coronary interventions: Rationale, results, and recommendations (Q35546867) (← links)
- Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromes (Q35579805) (← links)
- Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction (Q35582491) (← links)
- Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions (Q35847529) (← links)
- Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes (Q36160606) (← links)
- Medical treatment of patients with heart failure or left ventricular dysfunction undergoing percutaneous coronary intervention (Q36643735) (← links)
- Mechanical thrombectomy options in complex percutaneous coronary interventions. (Q36645800) (← links)
- Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group (Q36676028) (← links)
- Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention (Q36920261) (← links)
- Evolution of anticoagulant and antiplatelet therapy: benefits and risks of contemporary pharmacologic agents and their implications for myonecrosis and bleeding in percutaneous coronary intervention. (Q37070772) (← links)
- Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel. (Q37094692) (← links)
- Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin (Q37608567) (← links)
- Clinical applications of bivalirudin in the cardiac catheterization laboratory (Q37811622) (← links)
- Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures (Q37932844) (← links)
- 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi (Q37953885) (← links)
- Same day discharge after elective percutaneous coronary intervention (Q38192516) (← links)
- Anticoagulation in coronary intervention (Q38762278) (← links)
- Off-pump coronary artery bypass grafting using continuous heparin infusion (Q40434785) (← links)
- Vascular complications following coronary intervention correlate with long-term cardiac events (Q40507081) (← links)
- Comparison of anti-Xa activity after a single intravenous bolus of low-dose enoxaparin in patients with and without end-stage renal disease (Q43166177) (← links)
- Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures (Q43900387) (← links)
- A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention (Q44244531) (← links)
- Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial (Q44307919) (← links)
- The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration (Q44307922) (← links)
- Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). (Q44397625) (← links)
- A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study (Q44588117) (← links)
- Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy (Q44601542) (← links)
- Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction (Q44640403) (← links)
- Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study (Q44750904) (← links)
- Current trends in heparin use during arterial vascular interventional radiology (Q45389704) (← links)
- Low-dose heparin for elective percutaneous coronary intervention (Q46112749) (← links)